These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 23645285)

  • 1. Role of targeted agents in metastatic colorectal cancer.
    Prenen H; Vecchione L; Van Cutsem E
    Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Target Therapy in Unresectable or Metastatic Colorectal Cancer].
    Kim JH; Park SJ
    Korean J Gastroenterol; 2016 Dec; 68(6):303-311. PubMed ID: 28025473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatments in recurrent and metastatic colorectal cancer.
    Ciombor KK; Bekaii-Saab T
    J Natl Compr Canc Netw; 2013 Sep; 11 Suppl 4(Suppl 4):S18-27. PubMed ID: 24158967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
    Kasi PM; Hubbard JM; Grothey A
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):273-6. PubMed ID: 25579664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
    Hurwitz H
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
    Wang JX; Wu HL; Zhu M; Zhou R
    Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Options for Second-Line Treatment in Metastatic Colorectal Cancer.
    Lee JJ; Sun W
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):46-54. PubMed ID: 27057668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in colorectal cancer: current status and future challenges.
    Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
    Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of targeted therapy in the treatment of advanced colorectal cancer.
    Fakih M
    Curr Treat Options Oncol; 2008 Dec; 9(4-6):357-74. PubMed ID: 19238551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.
    Weinberg BA; Hartley ML; Salem ME
    Oncology (Williston Park); 2017 Jul; 31(7):539-48. PubMed ID: 28712098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
    Lee JJ; Chu E
    Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.